Brief: Brii Biosciences Announces Commercial Launch Of Long-Acting Covid-19 Neutralizing Antibody Therapy In China
07/07/2022 02:27
July 7 (Reuters) - Brii Biosciences Ltd 2137.HK :
* BRII BIOSCIENCES ANNOUNCES COMMERCIAL LAUNCH OF
LONG-ACTING
COVID-19 NEUTRALIZING ANTIBODY THERAPY IN CHINA BY JV
MAJORITY-OWNED BY CO
Source text for Eikon: ID:nHKSqjKMG
Further company coverage: 2137.HK
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR